{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GCSF&page=38", "query": { "intervention": "GCSF", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 1135, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GCSF&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GCSF&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T04:37:06.154Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07216703", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1023, "start_date": "2026-01-19", "completion_date": "2031-10-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216703" }, { "nct_id": "NCT00004189", "title": "Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "becatecarin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 3, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004189" }, { "nct_id": "NCT00007891", "title": "Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 monoclonal antibody BrE-3", "type": "RADIATION" }, { "name": "yttrium Y 90 monoclonal antibody BrE-3", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Cancer Research Institute of Contra Costa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-06", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 2, "location_summary": "San Francisco, California • Aurora, Colorado", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00007891" }, { "nct_id": "NCT00047320", "title": "Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor", "Central Nervous System Tumors", "Childhood Germ Cell Tumor" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "3 Years to 24 Years" }, "enrollment_count": 104, "start_date": "2004-01", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 90, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047320" }, { "nct_id": "NCT00075608", "title": "2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous stem cell transplantation", "type": "PROCEDURE" }, { "name": "stem cell infusion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2001-08", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2017-01-27", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075608" }, { "nct_id": "NCT00002635", "title": "Aminocamptothecin in Treating Patients With T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "aminocamptothecin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "1995-05", "completion_date": "2000-04", "has_results": false, "last_update_posted_date": "2013-07-26", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002635" }, { "nct_id": "NCT00003913", "title": "Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 390, "start_date": "1998-12", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 23, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003913" }, { "nct_id": "NCT00003573", "title": "Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumors", "Central Nervous System Tumors" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 53, "start_date": "1998-11", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2014-07-25", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 94, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003573" }, { "nct_id": "NCT00138229", "title": "Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-07", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-03-29", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00138229" }, { "nct_id": "NCT00187031", "title": "A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wilms Tumor" ], "interventions": [ { "name": "Topotecan, Filgrastim (G-CSF), Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 37, "start_date": "2002-11", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2008-06-04", "last_synced_at": "2026-10-19T04:37:06.154Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Memphis, Tennessee + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00187031" } ] }